Previous 10 | Next 10 |
Nes-Ziona, Israel, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage immunotherapy company, today announced the first presentation of its preclinical studies, which were designed to evaluate the combination of Enlivex’s Allocetra-OTS...
Nes-Ziona, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Israeli Patent Authority issued a notice of allowance for a patent application covering ALLOCETRA TM , the company’s immunotherapy produc...
Nes-Ziona, Israel, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage immunotherapy company, today announced that company management will make a corporate presentation at the 21st Annual Global Investment Conference, sponsored by H.C. Wainwright &am...
The safety review committee of Enlivex Therapeutics' (NASDAQ: ENLV ) announces positive recommendation for Company’s ongoing Phase Ib clinical trial in patients with severe sepsis. More news on: Enlivex Therapeutics Ltd., Healthcare stocks news, Read more ...
Nes Ziona, Israel, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the safety review committee of the Company’s ongoing Phase Ib clinical trial in patients with severe sepsis reviewed the data fo...
Gainers: DelMar Pharmaceuticals (NASDAQ: DMPI ) +39%. SigmaTron International (NASDAQ: SGMA ) +22% . Nuvectra Corporation (NASDAQ: NVTR ) +20% . Teradyne (NASDAQ: TER ) +18% . Manhattan Associates (NASDAQ: MANH ) +18% . Snap (NYSE: SNAP ) +16% . Acasti Pharma (NASDAQ: ACS...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) was in the red again last week, falling from 3,324.66 points on Monday’s open to 3,314.13 points as of 1:54 p.m. EDT on Friday (July 19). On Sunday (July 14), Gilead Sciences (NASDAQ: GILD ) announced its plans to play US$5.1 ...
The Company's shares, which currently trade on NASDAQ , will be dual-listed on the Tel Aviv Stock Exchange (TASE) starting on July 22, 2019, under the symbol ENLV Tel-Aviv, Israel, July 16, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., a clinical-stage immunothe...
Nes-Ziona, Israel, June 18, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Australian Patent Office (IP Australia) granted a new patent (#2013353573) covering ALLOCETRA TM , the company’s immunotherapy product....
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) was on the decline last week, dropping from 3,269.13 points on Monday (June 10) to 3,238.69 points as of 2:08 p.m. EDT on Friday (June 14). Last week, Provention Bio (NASDAQ: PRVB ) announced a public offering of its common stock on Monday...
News, Short Squeeze, Breakout and More Instantly...
Enlivex Therapeutics Ltd. Company Name:
ENLV Stock Symbol:
NASDAQ Market:
Enlivex Therapeutics Ltd. Website:
• First study of Allocetra TM in psoriatic arthritis, a chronic inflammatory condition that causes joint pain, swelling and stiffness, affects as many as 30% of people with psoriasis 1 , and has limited treatment options Nes-Ziona, Israel, July 23, 2024 (GLOB...
ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 20, at 7 p.m. Eastern T...
First patient dosed with Allocetra TM in thumb osteoarthritis, a degenerative, debilitating and progressive disease that affects millions of people Thumb osteoarthritis currently has no FDA-approved therapy and no effective long-term treatments Ness-Ziona, Israel, June 24, 2024 (GLO...